The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Bricanyl 500 micrograms/ml solution for injection or infusion

AstraZeneca ABPA1019/007/001

Main Information

Trade NameBricanyl 500 micrograms/ml solution for injection or infusion
Active SubstancesTerbutaline sulfate
Dosage FormSolution for injection/infusion
Licence HolderAstraZeneca AB
Licence NumberPA1019/007/001

Group Information

ATC CodeR03CC Selective beta-2-adrenoreceptor agonists
R03CC03 terbutaline


License statusAuthorised
Licence Issued01/04/1999
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back